Recercat. Dipósit de la Recerca de Catalunya
Publicación
Artículo científico (JournalArticle)
New mutations in HFE2 and TFR2 genes causing non HFE-related hereditary hemochromatosis
This study was supported by the grant RTI-2018-101735-B-I100 (MCI/AEI/FEDER, EU) from the Spanish Ministry of Science and Innovation (MICINN) to M.S. G.H. is supported by funds provided by the APU and ADISCON Patient associations. X.F.-C. is partially supported by funds provided by the grant RTI-2018-101735-B-I100 (MCI/AEI/FEDER, EU). V.V. is supported by funds provided by APU and ADISCON patient associations and is currently supported by funds provided by UIC postdoctoral scholarship and by funds provided by RETOS COLABORACION grant RTC2019-007074-1 (MCI/AEI/FEDER, EU) from the Spanish Ministry of Science and Innovation (MICINN). The work by M.F.P., P.M.M.T. and J.V.-F. has been developed within the BIO2017-83650-P project, funded by the Spanish Subprograma Estatal de Generación del Conocimiento. M.M. is supported by a Marie Curie Fellowship grant from the European Commission., Hereditary hemochromatosis (HH) is an iron metabolism disease clinically characterized by excessive iron deposition in parenchymal organs such as liver, heart, pancreas, and joints. It is caused by mutations in at least five different genes. HFE hemochromatosis is the most common type of hemochromatosis, while non-HFE related hemochromatosis are rare cases. Here, we describe six new patients of non-HFE related HH from five different families. Two families (Family 1 and 2) have novel nonsense mutations in the HFE2 gene have novel nonsense mutations (p.Arg63Ter and Asp36ThrfsTer96). Three families have mutations in the TFR2 gene, one case has one previously unreported mutation (Family A—p.Asp680Tyr) and two cases have known pathogenic mutations (Family B and D—p.Trp781Ter and p.Gln672Ter respectively). Clinical, biochemical, and genetic data are discussed in all these cases. These rare cases of non-HFE related hereditary hemochromatosis highlight the importance of an earlier molecular diagnosis in a specialized center to prevent serious clinical complications., info:eu-repo/semantics/publishedVersion